Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments.

The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity.

The Biopharmaceuticals segment involves in the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation, and therapy areas.

The company was founded by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen in 1923 is headquartered in Bagsvćrd, Denmark.
Sales per Businesses
20142015Delta
DKK (in Million)%DKK (in Million)%
Diabetes & Obesity Care69,98078.8%85,59079.3% +22.31%
Biopharmaceuticals18,82621.2%22,33720.7% +18.65%
Sales per Regions
20142015Delta
DKK (in Million)%DKK (in Million)%
North America43,12348.6%56,85752.7% +31.85%
Europe20,15022.7%20,79819.3% +3.22%
International12,54014.1%14,96613.9% +19.35%
Region China8,0889.1%9,8719.1% +22.05%
Japan & Korea4,9055.5%5,4355% +10.81%
Managers
NameAgeSinceTitle
Lars Fruergaard Jřrgensen, MBA511991President & Chief Executive Officer
Göran Ando682005Chairman
Jesper Brandgaard, MBA541999Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, PhD571991Chief Science Officer & Executive Vice President
Mads Krogsgaard--Chief Science Officer
Anne Marie Handrup Kverneland611981Director
Stig Strřbćk531992Director
Bruno Francois Jules Angelici, MBA702011Independent Non-Executive Director
Elizabeth Anne Hewitt612012Independent Director
Sřren Thuesen Pedersen, MBA531994Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 2,012,564,000 1,803,082,748 89.6% 45,667,252 2.3% 70.7%
Share B 10 537,436,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk Fonden 163,814,000 8.14%
Capital Research & Management Co. (World Investors) 94,116,943 4.68%
Novo Nordisk A/S 58,744,130 2.92%
Norges Bank Investment Management 42,958,316 2.13%
The Vanguard Group, Inc. 39,544,187 1.96%
Northern Cross LLC 24,349,163 1.21%
Alecta Pension Insurance Mutual 20,908,000 1.04%
BlackRock Fund Advisors 16,252,226 0.81%
Swedbank Robur Fonder AB 15,365,769 0.76%
Jupiter Asset Management Ltd. 15,207,312 0.76%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 58,744,1302.92%2,092,786,066 USD
Nnit A/S (NNIT) 6,375,00025.5%174,982,148 USD
Innate Pharma (IPH) 5,422,70810.1%58,774,129 USD
Pieris Pharmaceuticals Inc (PIRS) 0
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVO NORDISK A/S-8.05%67 736
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.60%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
SANOFI7.76%115 582
GLAXOSMITHKLINE PLC6.95%102 400
BAYER AG7.89%95 518
ELI LILLY AND CO14.45%92 880
BRISTOL-MYERS SQUIBB C..-4.36%92 079
ALLERGAN PLC13.01%79 559
ASTRAZENECA PLC11.76%78 074
ABBOTT LABORATORIES16.45%77 293
SHIRE PLC-0.16%52 993
TAKEDA PHARMACEUTICAL ..8.83%37 345
TEVA PHARMACEUTICAL IN..-12.65%33 487
ASTELLAS PHARMA INC-6.52%29 396
MYLAN NV7.37%21 934
CHUGAI PHARMACEUTICAL ..15.80%19 524
JIANGSU HENGRUI MEDICI..17.89%18 247
Sector Pharmaceuticals - NEC
Novo Nordisk A/S : Connections
Novo Nordisk China Pharmaceuticals Co. Ltd.
EUSA Pharma (Europe) Ltd.
Bio*One Capital Pte Ltd.
RAND Health
Symphogen A/S
The International Centre for Missing & Exploited Children
Novo Nordisk Region North America Ii A/S
Essex Woodlands Health Ventures UK Ltd.
University of Copenhagen
Novo A/S
SWMF Life Science Venture Fund LP
Novo Nordisk Region Japan & Korea A/S
Novo Nordisk Region China A/S
Archimedes Pharma UK Ltd.
Novo Nordisk Holding Ltd.
Essex Bidco Ltd.
Steno Diabetes Center A/S
Novo Nordisk Fonden
Hofor Forsyning Komplementar A/S
Harno Invest A/S
NNE Pharmaplan A/S
Novo Nordisk Region Europe A/S
Novo Nordisk Region International Operations A/S
Novo Nordisk Gsc Holding A/S
Silverwood Property Ltd.
Novo Nordisk Pharmaceuticals A/S
HOFOR Forsyning Holding A/S
Novo Nordisk Invest 2 A/S
Hofor Forsyning A/S
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsvćrd, Capital Region 2880

Phone : +45.44.44.88.88
Web : www.novonordisk.com
© 2017 People , Fundamentals and Ownership